Jasper Issuance Of Capital Stock vs Begin Period Cash Flow Analysis

JSPRW Stock

USD 0.20 0.01 5.26%

Jasper Therapeutics financial indicator trend analysis is infinitely more than just investigating Jasper Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jasper Therapeutics is a good investment. Please check the relationship between Jasper Therapeutics Issuance Of Capital Stock and its Begin Period Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Jasper Stock please use our How to Invest in Jasper Therapeutics guide.

Issuance Of Capital Stock vs Begin Period Cash Flow

Issuance Of Capital Stock vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jasper Therapeutics Issuance Of Capital Stock account and Begin Period Cash Flow. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Jasper Therapeutics' Issuance Of Capital Stock and Begin Period Cash Flow is 0.84. Overlapping area represents the amount of variation of Issuance Of Capital Stock that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Jasper Therapeutics, assuming nothing else is changed. The correlation between historical values of Jasper Therapeutics' Issuance Of Capital Stock and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Issuance Of Capital Stock of Jasper Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Issuance Of Capital Stock i.e., Jasper Therapeutics' Issuance Of Capital Stock and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Issuance Of Capital Stock

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Jasper Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jasper Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Jasper Stock please use our How to Invest in Jasper Therapeutics guide.Selling General Administrative is likely to drop to about 11.2 M in 2024. Issuance Of Capital Stock is likely to drop to about 61.9 M in 2024

	2010	2023	2024 (projected)
Interest Income	701K	5.2M	3.2M
Net Interest Income	701K	5.2M	3.2M

Interest Income Net Interest Income

Jasper Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Warrants	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Total Current Assets	Non Current Liabilities Other	Common Stock	Short Long Term Debt Total
Total Assets		0.85	0.93	0.83	-0.78	-0.78	-0.96	-0.81	0.98	1.0	0.84	0.87	1.0	0.82	-0.73	-0.53	-0.02	0.77	0.79	0.87	0.29	0.7	1.0	-0.91	-0.7	0.77
Other Current Liab	0.85		0.98	0.64	-0.9	-0.91	-0.8	-0.94	0.9	0.82	0.88	0.98	0.82	0.95	-0.82	-0.63	0.14	0.89	0.68	0.88	0.45	0.86	0.83	-0.67	-0.86	0.78
Total Current Liabilities	0.93	0.98		0.71	-0.9	-0.91	-0.87	-0.94	0.96	0.9	0.93	0.98	0.9	0.95	-0.85	-0.6	0.11	0.9	0.78	0.9	0.44	0.8	0.91	-0.79	-0.85	0.83
Total Stockholder Equity	0.83	0.64	0.71		-0.59	-0.58	-0.9	-0.73	0.73	0.85	0.6	0.62	0.85	0.49	-0.38	-0.68	-0.51	0.38	0.68	0.89	-0.18	0.69	0.84	-0.76	-0.39	0.69
Net Tangible Assets	-0.78	-0.9	-0.9	-0.59		1.0	0.8	0.96	-0.86	-0.74	-0.9	-0.93	-0.74	-0.94	0.92	0.76	-0.31	-0.89	-0.69	-0.87	-0.63	-0.77	-0.75	0.74	0.97	-0.81
Warrants	-0.78	-0.91	-0.91	-0.58	1.0		0.8	0.95	-0.87	-0.74	-0.91	-0.94	-0.74	-0.94	0.93	0.75	-0.32	-0.9	-0.7	-0.87	-0.64	-0.76	-0.75	0.74	0.97	-0.81
Net Debt	-0.96	-0.8	-0.87	-0.9	0.8	0.8		0.84	-0.93	-0.96	-0.76	-0.8	-0.96	-0.74	0.65	0.72	0.1	-0.66	-0.7	-0.92	-0.23	-0.77	-0.96	0.88	0.68	-0.72
Retained Earnings	-0.81	-0.94	-0.94	-0.73	0.96	0.95	0.84		-0.85	-0.78	-0.89	-0.94	-0.78	-0.89	0.81	0.81	-0.04	-0.81	-0.73	-0.96	-0.39	-0.86	-0.79	0.71	0.87	-0.86
Accounts Payable	0.98	0.9	0.96	0.73	-0.86	-0.87	-0.93	-0.85		0.96	0.89	0.92	0.96	0.9	-0.83	-0.55	0.17	0.87	0.76	0.85	0.48	0.71	0.97	-0.89	-0.82	0.76
Cash	1.0	0.82	0.9	0.85	-0.74	-0.74	-0.96	-0.78	0.96		0.79	0.82	1.0	0.77	-0.66	-0.53	-0.06	0.72	0.73	0.85	0.24	0.7	1.0	-0.89	-0.65	0.71
Non Current Assets Total	0.84	0.88	0.93	0.6	-0.9	-0.91	-0.76	-0.89	0.89	0.79		0.96	0.79	0.93	-0.94	-0.49	0.23	0.94	0.91	0.84	0.53	0.57	0.81	-0.85	-0.88	0.94
Non Currrent Assets Other	0.87	0.98	0.98	0.62	-0.93	-0.94	-0.8	-0.94	0.92	0.82	0.96		0.82	0.98	-0.91	-0.58	0.21	0.95	0.79	0.87	0.53	0.75	0.84	-0.76	-0.9	0.86
Cash And Short Term Investments	1.0	0.82	0.9	0.85	-0.74	-0.74	-0.96	-0.78	0.96	1.0	0.79	0.82		0.77	-0.66	-0.53	-0.06	0.72	0.73	0.85	0.24	0.7	1.0	-0.89	-0.65	0.71
Common Stock Total Equity	0.82	0.95	0.95	0.49	-0.94	-0.94	-0.74	-0.89	0.9	0.77	0.93	0.98	0.77		-0.94	-0.53	0.39	0.98	0.71	0.79	0.68	0.71	0.79	-0.72	-0.95	0.78
Retained Earnings Total Equity	-0.73	-0.82	-0.85	-0.38	0.92	0.93	0.65	0.81	-0.83	-0.66	-0.94	-0.91	-0.66	-0.94		0.45	-0.52	-0.97	-0.77	-0.7	-0.78	-0.5	-0.69	0.76	0.96	-0.81
Short Term Investments	-0.53	-0.63	-0.6	-0.68	0.76	0.75	0.72	0.81	-0.55	-0.53	-0.49	-0.58	-0.53	-0.53	0.45		0.11	-0.39	-0.33	-0.81	-0.19	-0.85	-0.53	0.43	0.63	-0.51
Non Current Liabilities Total	-0.02	0.14	0.11	-0.51	-0.31	-0.32	0.1	-0.04	0.17	-0.06	0.23	0.21	-0.06	0.39	-0.52	0.11		0.49	-0.05	-0.18	0.93	-0.11	-0.05	-0.06	-0.52	-0.04
Capital Surpluse	0.77	0.89	0.9	0.38	-0.89	-0.9	-0.66	-0.81	0.87	0.72	0.94	0.95	0.72	0.98	-0.97	-0.39	0.49		0.74	0.7	0.74	0.56	0.74	-0.73	-0.94	0.78
Other Current Assets	0.79	0.68	0.78	0.68	-0.69	-0.7	-0.7	-0.73	0.76	0.73	0.91	0.79	0.73	0.71	-0.77	-0.33	-0.05	0.74		0.78	0.23	0.35	0.76	-0.89	-0.62	0.97
Other Stockholder Equity	0.87	0.88	0.9	0.89	-0.87	-0.87	-0.92	-0.96	0.85	0.85	0.84	0.87	0.85	0.79	-0.7	-0.81	-0.18	0.7	0.78		0.19	0.83	0.86	-0.79	-0.74	0.87
Total Liab	0.29	0.45	0.44	-0.18	-0.63	-0.64	-0.23	-0.39	0.48	0.24	0.53	0.53	0.24	0.68	-0.78	-0.19	0.93	0.74	0.23	0.19		0.2	0.26	-0.35	-0.79	0.28
Long Term Investments	0.7	0.86	0.8	0.69	-0.77	-0.76	-0.77	-0.86	0.71	0.7	0.57	0.75	0.7	0.71	-0.5	-0.85	-0.11	0.56	0.35	0.83	0.2		0.7	-0.42	-0.66	0.51
Total Current Assets	1.0	0.83	0.91	0.84	-0.75	-0.75	-0.96	-0.79	0.97	1.0	0.81	0.84	1.0	0.79	-0.69	-0.53	-0.05	0.74	0.76	0.86	0.26	0.7		-0.9	-0.66	0.73
Non Current Liabilities Other	-0.91	-0.67	-0.79	-0.76	0.74	0.74	0.88	0.71	-0.89	-0.89	-0.85	-0.76	-0.89	-0.72	0.76	0.43	-0.06	-0.73	-0.89	-0.79	-0.35	-0.42	-0.9		0.67	-0.82
Common Stock	-0.7	-0.86	-0.85	-0.39	0.97	0.97	0.68	0.87	-0.82	-0.65	-0.88	-0.9	-0.65	-0.95	0.96	0.63	-0.52	-0.94	-0.62	-0.74	-0.79	-0.66	-0.66	0.67		-0.73
Short Long Term Debt Total	0.77	0.78	0.83	0.69	-0.81	-0.81	-0.72	-0.86	0.76	0.71	0.94	0.86	0.71	0.78	-0.81	-0.51	-0.04	0.78	0.97	0.87	0.28	0.51	0.73	-0.82	-0.73

Click cells to compare fundamentals

Jasper Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jasper Issuance Of Capital Stock vs Begin Period Cash Flow Analysis

Issuance Of Capital Stock vs Begin Period Cash Flow

Issuance Of Capital Stock vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Issuance Of Capital Stock

Begin Period Cash Flow

Jasper Therapeutics fundamental ratios Correlations

Jasper Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Jasper Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Warrants	+ 1.0	Net Tangible Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Capital Surpluse	- 0.97	Retained Earnings Total Equity
Other Stockholder Equity	- 0.96	Retained Earnings
Total Current Assets	- 0.96	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt
Net Debt	- 0.96	Total Assets